A case of atopic dermatitis with a severe resistant course in adult patient with atopic march

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Introduction. The atopic march is the natural course of development of atopy symptoms. It is characterized by a typical sequence of development of clinical symptoms of atopic disease, when some symptoms become more significant, others are recede. Timely allergological diagnostics with the identification of causal allergens allows to preventor suspend the atopic march.

Purpose of the study was to demonstrate the stages of the atopic march formation and clinical manifestations of atopy, the importance of on timely detection of causal allergens, the capability of modern diagnostics and treatment of severe resistant forms of allergic diseases.

 

Restricted Access

Galiya M. Tusupbekova

Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan

Author for correspondence.
Email: Galiya.tgm@gmail.com
ORCID iD: 0000-0001-6371-9176

Kazakhstan, 5/2, Uly Dala st., flat 396, Nur-Sultan, 010000

Head of the Allergy service and the Center of Allergy

Aigul A. Syzdykova

Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan

Email: aigul18_04@list.ru
ORCID iD: 0000-0003-3300-684X

Kazakhstan, 5/2, Uly Dala st., flat 396, Nur-Sultan, 010000

allergologist-immunologist

Botagoz M. Davletova

Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan

Email: botashadavletova@mail.ru
ORCID iD: 0000-0002-4505-9319

Russian Federation, 5/2, Uly Dala st., flat 396, Nur-Sultan, 010000

allergologist-immunologist

  1. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J. Allergy Clin Immunol. 2017;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004.
  2. Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350-358. doi: 10.1016/j.jaci.2016.06.002.
  3. Кудрявцева АВ. Нарушение кожного барьера как ведущий фактор формирования местного воспалительного процесса при атопическом дерматите. Вестник дерматологии и венерологии. 2017;(4):82-89 [Kudryavtseva AV. Breach of skin barrier as a leading factorin the formation of local inflammatory process in atopic dermatitis. Vestnik Dermatologii i Venerologii. 2017;(4):82-89 (In Russ.)]. doi: 10.25208/0042-4609-2017-93-4-82-89.
  4. Патрушев АВ, Гутка ВО, Сухарев АВ, Самцов АВ, Завальская ЕИ. Оценка вегетативных, нейрогуморальных и психоэмоциональных нарушений у больных атопическим дерматитом различной степени тяжести. Вестник дерматологии и венерологии. 2016;(5):25-31 [Patrushev AV, Gutka VO, Sukharev AV, Samtsov AV, Zavalskaya EI. Assessment of vegetative, neurohumoral and psycho-emotional disorders in patients with atopic dermatitis of varying severity. Vestnik Dermatologii i Venerologii. 2016;(5):25-31 (In Russ.)]. doi: 10.25208/0042-4609-2016-92-5-25-31.
  5. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023). doi: 10.1016/S0140-6736(15)00149-X.
  6. Варламов ЕЕ, Пампура АН, Сухоруков ВС. Значение цитокинов в патогенезе атопического дерматита. Российский вестник перинатологии и педиатрии. 2018;63:(1):28-33 [Varlamov EE, Pampura AN, Sukhorukov VS. The importance of cytokines for the atopic dermatitis pathogenesis. Rossiyskiy Vestnik Perinatologii i Pediatrii. 2018;63:(1):28-33 (In Russ.)]. doi: 10.21508/1027-4065-2018-63-1-28-33.
  7. Van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: Pros and cons in allergology. J Allergy Clin Immunol. 2017;140(4):974-977. doi: 10.1016/j.jaci.2017.05.008.
  8. Konopka E, Ceregra A, Maciorkowska E, Surowska B, Trojanowska I, Roszko-Kirpsza I, Cukrowska B. Specific IgE Antibodies in Young Children with Atopic Dermatitis – Correlation of Multiple Allergen Simultaneous Immunoblot Test and ImmunoCap System. Clin Lab. 2016;62(5):815-821. doi: 10.7754/clin.lab.2015.150816.
  9. Gandhi NA, Bennett BL, Graham NM et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50. doi: 10.1038/nrd4624.
  10. Wei W, Anderson P, Gadkari A et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150-157. doi: 10.1111/1346-8138.14116.

Views

Abstract - 43

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies